Submitted by Jennifer Fuson on Tue, 07/09/2013 - 16:07
After 23 months, the U.S Food and Drug Administration (FDA) has finally agreed to look at the huge safety discrepancy between generic and brand named drugs. The FDA signaled the move by notifying the Office of Management and Budget of its plans to publish a proposed new rule that would make create similar requirements for generic and brand-name drug makers with respect to how they update their warning labels.